Ultra-LEAF™ Purified anti-human IL-13 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

COS-expressed, recombinant human IL-13

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

ELISA Capture - Quality tested
ELISPOT Capture, Neut, ICFC, IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA applications, a concentration range of 1.0 - 4.0 µg/mL is recommended. To obtain a linear standard curve, serial dilutions of human IL-13 recombinant protein ranging from 2000 to 8 pg/mL are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA or ELISPOT Capture^1,2: The Ultra-LEAF™ Purified JES10-5A2 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated Poly5020 antibody (Cat. No. 502001) as the detecting antibody. The Ultra-LEAF™ Purified antibody is suggested for ELISPOT capture.

Application References

(PubMed link indicates BioLegend citation)

1. McKenzie, A., et al. 1994. Curr. Prot. Immunol.. John Wiley & Sons. New York. Section 6.18.
2. Abrams, J. 1995. Curr. Prot. Immunol.. John Wiley and Sons, New York. Unit 6.20.
3. Schaerli, P., et al. 2000. J. Exp. Med. 192:1553.
4. Andersson, J., et al. 1994. Immunology 83:16.
5. Skansen-Saphir, U., et al. 1994. Eur. J. Immunol. 24:916.
6. Andersson, U., et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag.
7. Gelfand, E. W., et al. 2006. J. Aller. and Clinic. Immunol. 117:577.
8. Knorr, C., et al. 1999. Am. J. Pathol. 155:2019.

RRID

AB_2820084 (BioLegend Cat. No. 501917)
AB_2820084 (BioLegend Cat. No. 501918)

Antigen Details

Structure

Cytokine; 17 kD (Mammalian)

Bioactivity

Suppression of macrophage cytotoxic activity; upregulation of IL-1RA expression; suppression of IL-1, IL-6, IL-8, IL-10, IL-12, chemokines MCP, MIP-1; differentiation of B cells, monocytes

Cell Sources

Activated T cells, mast cells, NK cells

Cell Targets

B cells, monocytes, macrophages, basophils

Receptors

Moderate affinity IL-13Rα1; high affinity heterodimer IL-13Rα1/IL-4Rα also binds IL-4; both receptor complexes have γ-subunit in common with IL-2R, IL-4R, IL-7R, IL-15R ; high affinity IL-13Rα2 incapable of signaling

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald, K., et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Hilton, D., et al. 1996. P. Natl. Acad. Sci. USA 93:497.
3. Obiri, N., et al. 1995. J. Biol. Chem. 270:8797.
4. Ochensberger, B., et al. 1996. Blood 88:3028.

Regulation

IL-13Rα2 possible antagonist

Gene ID

3596 View all products for this Gene ID

UniProt

View information about IL-13 on UniProt.org

Related Protocols

• Active Protocols: Sandwich ELISA - Video
• Sandwich ELISA Protocol

Other Formats